PH12013500689A1 - A combination composition - Google Patents

A combination composition

Info

Publication number
PH12013500689A1
PH12013500689A1 PH1/2013/500689A PH12013500689A PH12013500689A1 PH 12013500689 A1 PH12013500689 A1 PH 12013500689A1 PH 12013500689 A PH12013500689 A PH 12013500689A PH 12013500689 A1 PH12013500689 A1 PH 12013500689A1
Authority
PH
Philippines
Prior art keywords
approximately
combination
combination composition
paracetamol
ibuprofen
Prior art date
Application number
PH1/2013/500689A
Other languages
English (en)
Inventor
Hartley Campbell Atkinson
Original Assignee
Aft Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46024668&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12013500689(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aft Pharmaceuticals Ltd filed Critical Aft Pharmaceuticals Ltd
Publication of PH12013500689A1 publication Critical patent/PH12013500689A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
PH1/2013/500689A 2010-11-04 2011-10-26 A combination composition PH12013500689A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ58901110 2010-11-04
PCT/NZ2011/000226 WO2012060719A1 (en) 2010-11-04 2011-10-26 A combination composition

Publications (1)

Publication Number Publication Date
PH12013500689A1 true PH12013500689A1 (en) 2013-05-27

Family

ID=46024668

Family Applications (2)

Application Number Title Priority Date Filing Date
PH1/2013/500689A PH12013500689A1 (en) 2010-11-04 2011-10-26 A combination composition
PH12021550804A PH12021550804A1 (en) 2010-11-04 2021-04-08 A combination composition

Family Applications After (1)

Application Number Title Priority Date Filing Date
PH12021550804A PH12021550804A1 (en) 2010-11-04 2021-04-08 A combination composition

Country Status (28)

Country Link
US (6) US20130225685A1 (enExample)
EP (1) EP2635269B1 (enExample)
JP (2) JP2013541583A (enExample)
KR (1) KR101900520B1 (enExample)
CN (2) CN107519159A (enExample)
AU (1) AU2011324137B2 (enExample)
BR (1) BR112013010829B8 (enExample)
CA (1) CA2814057C (enExample)
CL (1) CL2013001250A1 (enExample)
CO (1) CO6771406A2 (enExample)
CY (1) CY1123398T1 (enExample)
DK (1) DK2635269T3 (enExample)
ES (1) ES2742373T3 (enExample)
HR (1) HRP20191489T1 (enExample)
HU (1) HUE045442T2 (enExample)
LT (1) LT2635269T (enExample)
MX (2) MX2013005113A (enExample)
MY (1) MY160572A (enExample)
NZ (1) NZ609727A (enExample)
PH (2) PH12013500689A1 (enExample)
PL (1) PL2635269T3 (enExample)
PT (1) PT2635269T (enExample)
RS (1) RS59258B1 (enExample)
RU (2) RU2013123646A (enExample)
SG (1) SG189319A1 (enExample)
SI (1) SI2635269T1 (enExample)
SM (1) SMT201900481T1 (enExample)
WO (1) WO2012060719A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011324137B2 (en) 2010-11-04 2015-05-07 Aft Pharmaceuticals Limited A combination composition
US9072710B2 (en) 2012-03-16 2015-07-07 Cumberland Pharmaceuticals Inc. Injectable ibuprofen formulation
WO2016008546A1 (en) * 2014-07-18 2016-01-21 Everbright Pharmaceuticals S.A.R.L. Aqueous formulation comprising paracetamol and ibuprofen
EP3203996A4 (en) * 2014-10-06 2018-05-16 Cumberland Pharmaceuticals, Inc. Co-administration of intravenous ibuprofen and acetaminophen for treatment of pain
WO2018192664A1 (en) 2017-04-20 2018-10-25 Hyloris Developments Sa METHOD FOR PREPARING A COMPOSITION WITH A LOW DISSOLVED OXYGEN CONTENT, COMPRISING ACETAMINOPHEN, AND OPTIONALLY ONE OR MORE NSAIDs, AND A COMPOSITION OBTAINED THEREOF
KR102642847B1 (ko) * 2017-07-10 2024-03-04 젤 캡 테크놀로지스 엘엘씨 이중 방출 투여형 캡슐 및 이를 제조하기 위한 방법, 장치 및 시스템
US11197830B2 (en) 2019-02-27 2021-12-14 Aft Pharmaceuticals Limited Pharmaceutical composition containing acetaminophen and ibuprofen
US11568752B2 (en) * 2020-01-28 2023-01-31 David Clark Company Incorporated Gateway retrieval alert device for aircraft pushback operations
WO2023281089A2 (en) 2021-07-08 2023-01-12 Krka, D.D., Novo Mesto Pharmaceutical composition comprising naproxen and paracetamol
GR1010809B (el) * 2023-09-13 2024-10-25 Ιουλια Τσετη Υδατικο διαλυμα ιβουπροφαινης παρακεταμολης για χρηση σε ενδοφλεβια χορηγηση
GR1010769B (el) * 2023-07-27 2024-09-18 Ιουλια Κλεωνος Τσετη Υδατικο διαλυμα ιβουπροφαινης για χρηση σε ενδοφλεβια χορηγηση
AU2024281739A1 (en) 2023-06-02 2025-11-27 Ioulia Tseti Pharmaceutical composition comprising ibuprofen

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3990895A (en) * 1995-12-05 1997-06-27 Adcock Ingram Limited Pharmaceutical composition comprising a skeletal muscle relaxant, a non-steroidal antiinflammatory agent and an analgesic
KR100851679B1 (ko) * 2001-11-02 2008-08-13 큠버랜드 파마슈티컬즈 인코포레이티드 2-(4-이소부틸페닐)프로피온산의 약학 조성물
JP2006514982A (ja) * 2003-03-21 2006-05-18 マクニール−ピーピーシー・インコーポレイテッド 非ステロイド抗炎症薬投薬計画
EP1781277B1 (en) * 2004-07-07 2012-02-01 AFT Pharmaceuticals Limited A combination composition comprising ibuprofen and paracetamol
KR20060072839A (ko) * 2004-12-23 2006-06-28 김경태 아세트아미노펜과 이부프로펜을 이용하여 통증조절과 해열작용을 하는 주사제
US7934627B2 (en) * 2005-10-13 2011-05-03 Alcoa Inc. Apparatus and method for high pressure extrusion with molten aluminum
MX2009004203A (es) * 2006-10-20 2009-07-02 Mcneil Ppc Inc Combinaciones de paracetamol/ibuprofeno y metodo para su uso.
WO2008079818A2 (en) * 2006-12-21 2008-07-03 Soluprin Pharmaceuticals, Inc. Intravenous administration of water soluble analgesic formulations
US20090264530A1 (en) * 2008-04-16 2009-10-22 Nickell Robert P Combined nsaid and acetaminophen formulation and method
HRP20190891T1 (hr) * 2008-10-14 2019-07-12 Aft Pharmaceuticals Limited Medicinski proizvod i tretman
WO2010105129A1 (en) * 2009-03-12 2010-09-16 Cumberland Pharmaceuticals Administration of intravenous ibuprofen
NZ604009A (en) * 2010-07-07 2015-03-27 Aft Pharmaceuticals Ltd A combination composition comprising ibuprofen and paracetamol
AU2011324137B2 (en) 2010-11-04 2015-05-07 Aft Pharmaceuticals Limited A combination composition
EP3203996A4 (en) * 2014-10-06 2018-05-16 Cumberland Pharmaceuticals, Inc. Co-administration of intravenous ibuprofen and acetaminophen for treatment of pain

Also Published As

Publication number Publication date
CA2814057C (en) 2022-02-01
US11446266B2 (en) 2022-09-20
AU2011324137A1 (en) 2013-05-02
US20190029982A1 (en) 2019-01-31
MX367209B (es) 2019-07-22
US12220392B2 (en) 2025-02-11
PH12021550804A1 (en) 2022-02-14
CY1123398T1 (el) 2021-10-29
JP2013541583A (ja) 2013-11-14
US20160235695A1 (en) 2016-08-18
HRP20191489T1 (hr) 2019-11-15
ES2742373T3 (es) 2020-02-14
CA2814057A1 (en) 2012-05-10
RU2015103107A3 (enExample) 2018-08-20
US20250134839A1 (en) 2025-05-01
AU2011324137B2 (en) 2015-05-07
MY160572A (en) 2017-03-15
US20240207210A1 (en) 2024-06-27
WO2012060719A1 (en) 2012-05-10
CL2013001250A1 (es) 2013-08-30
SI2635269T1 (sl) 2019-10-30
LT2635269T (lt) 2019-09-10
DK2635269T3 (da) 2019-08-26
BR112013010829A2 (pt) 2016-08-16
EP2635269A1 (en) 2013-09-11
KR20140025314A (ko) 2014-03-04
RU2707089C2 (ru) 2019-11-22
MX2013005113A (es) 2013-06-03
RU2013123646A (ru) 2014-12-10
US20230000805A1 (en) 2023-01-05
RS59258B1 (sr) 2019-10-31
CN107519159A (zh) 2017-12-29
BR112013010829B8 (pt) 2022-01-04
JP2017132791A (ja) 2017-08-03
HUE045442T2 (hu) 2019-12-30
PL2635269T3 (pl) 2019-11-29
CO6771406A2 (es) 2013-10-15
CN103298464A (zh) 2013-09-11
PT2635269T (pt) 2019-09-04
RU2015103107A (ru) 2015-06-20
EP2635269B1 (en) 2019-05-22
SG189319A1 (en) 2013-05-31
SMT201900481T1 (it) 2019-11-13
NZ609727A (en) 2015-07-31
US11896567B2 (en) 2024-02-13
KR101900520B1 (ko) 2018-09-19
EP2635269A4 (en) 2014-09-17
BR112013010829B1 (pt) 2021-12-21
JP6353577B2 (ja) 2018-07-04
US20130225685A1 (en) 2013-08-29

Similar Documents

Publication Publication Date Title
PH12021550804A1 (en) A combination composition
MY173215A (en) Acetylcysteine compositions and methods of use thereof
CY1116727T1 (el) Θεραπεια πολλαπλης σκληρυνσης me laquinimod
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
WO2015151079A3 (en) Auristatin analogues and their conjugates with cell-binding molecules
GB0807605D0 (en) Lipid composition
MX370629B (es) El uso de amisulpride como un anti-emetico.
WO2012087742A3 (en) Methods and compositions suitable for managing blood glucose in animals
EP4424323A3 (en) Anti-folr1 immunoconjugate dosing regimens
PH12017502379A1 (en) Drospirenone-based contraceptive for a female patient affected with excess weight
AR089509A1 (es) Metodo para tratar la perdida osea alveolar, un implante dental, un anticuerpo antiesclerostina, un gel o matriz que comprende dicho anticuerpo y uso
MY173582A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
IN2014DN08598A (enExample)
NZ630494A (en) Administration of lorcaserin to individuals with renal impairment
MY164112A (en) A combination composition comprising ibuprofen and paracetamol
WO2009012472A3 (en) Methods and compositions for treating conditions
MX2016008027A (es) Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington.
MX2013010947A (es) Complejos de galio, composiciones farmacéuticas y métodos de uso.
PH12015500070B1 (en) Pediatric oral liquid compositions containing nepadutant
MX366118B (es) Combinacion sinergistica de paracetamol/celecoxib para el tratamiento de dolor inflamatorio.
BR112015011408A2 (pt) comprimido dispersível
MX2022010593A (es) Composiciones tópicas de diclofenaco y métodos.
PH12019501607A1 (en) Tapentadol nasal composition
MY154883A (en) A combination composition
SA515360445B1 (ar) قرص قابل للتشتيت